Ophthalmic Panel To Eye Alcon’s AcrySof IQ Restor Multifocal IOL
This article was originally published in The Gray Sheet
Executive Summary
FDA’s ophthalmic devices advisory panel plans to meet on Nov. 14 to assess Alcon Laboratories’ PMA application for its AcrySof IQ Restor multifocal toric posterior chamber intraocular lens.
You may also be interested in...
All Eyes On Ophthalmic Devices Market
In the ophthalmic device sector, intraocular lens surgery is expanding way beyond the cataract market with paradigm shifting technology. The vast presbyopia market now has an FDA-approved "corneal inlay" option, micro invasive glaucoma surgery has created an entirely new device segment, and corneal cross-linking has the potential to transcend its role as an effective treatment for a corneal disease to possibly being the next big thing in the non-surgical treatment of refractive errors.
FDA Advisors Recommend Alcon’s Multifocal Toric IOL
The company received a resounding yes from an FDA panel to approve the lens for cataract surgery to treat presbyobia and astigmatisms..
Alcon Plans PMA Submission In 2011 For Presbyopia/Toric Lens
Alcon plans to submit a PMA in 2011 for an AcrySof IQ ReSTOR Toric lens for presbyopia and astigmatism correction, the company reported during its July 27 second-quarter earnings call